Headlines about Portola Pharmaceuticals (NASDAQ:PTLA) have trended somewhat positive this week, Alpha One Sentiment reports. The research firm, a service of Accern, scores the sentiment of press coverage by monitoring more than 20 million news and blog sources. Alpha One ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Portola Pharmaceuticals earned a news impact score of 0.09 on Alpha One’s scale. Alpha One also assigned news coverage about the biopharmaceutical company an impact score of 76 out of 100, meaning that recent press coverage is likely to have an impact on the stock’s share price in the immediate future.
These are some of the media stories that may have effected Alpha One Sentiment’s scoring:
- Portola Pharmaceuticals, Inc.’s (PTLA) is at $39.41 per share and Steris Plc’s (STE) is listed at $74.15 – Stocks Gallery (stocksgallery.com)
- The Macquarie Group Ltd. Has $880000 Position in Portola Pharmaceuticals Inc (PTLA) – BangaloreWeekly (bangaloreweekly.com)
- Portola Pharmaceuticals Announces Phase 2a Safety and Efficacy Cerdulatinib Data to be Presented at the European Hematology Association (EHA) (finance.yahoo.com)
- A CLOSER LOOK AT MARKET CAPS AND WHY THEY’RE IMPORTANT (usfinancialnewstoday.com)
- Can Portola Pharmaceuticals Inc (PTLA) Continue its Near-Term Run? – DARC News (darcnews.com)
PTLA has been the topic of several research reports. Vetr lowered shares of Portola Pharmaceuticals from a “buy” rating to a “sell” rating and set a $36.36 price objective on the stock. in a report on Wednesday, March 1st. Citigroup Inc set a $51.00 price objective on shares of Portola Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday, April 12th. Cowen and Company set a $40.00 price objective on shares of Portola Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday, February 8th. Oppenheimer Holdings Inc. raised shares of Portola Pharmaceuticals from a “market perform” rating to an “outperform” rating and lifted their price objective for the company from $28.00 to $40.00 in a report on Friday, February 24th. Finally, Morgan Stanley lifted their price objective on shares of Portola Pharmaceuticals from $31.00 to $47.00 and gave the company an “overweight” rating in a report on Monday, March 6th. Two equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $39.90.
Portola Pharmaceuticals (NASDAQ:PTLA) traded down 2.02% during trading on Friday, reaching $38.88. 535,059 shares of the company’s stock traded hands. Portola Pharmaceuticals has a 12-month low of $15.68 and a 12-month high of $42.74. The company has a 50 day moving average price of $39.07 and a 200-day moving average price of $29.57. The company’s market cap is $2.22 billion.
Portola Pharmaceuticals (NASDAQ:PTLA) last announced its quarterly earnings data on Monday, May 8th. The biopharmaceutical company reported ($0.74) EPS for the quarter, beating the Zacks’ consensus estimate of ($1.20) by $0.46. Portola Pharmaceuticals had a negative net margin of 1,072.67% and a negative return on equity of 82.19%. The company had revenue of $5.12 million for the quarter, compared to the consensus estimate of $4.21 million. During the same period in the prior year, the firm posted ($1.15) EPS. The company’s quarterly revenue was down 37.9% compared to the same quarter last year. On average, equities research analysts forecast that Portola Pharmaceuticals will post ($4.44) EPS for the current fiscal year.
In other Portola Pharmaceuticals news, EVP Tao Fu sold 1,097 shares of the stock in a transaction that occurred on Monday, April 10th. The shares were sold at an average price of $36.97, for a total value of $40,556.09. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CEO William Lis sold 6,750 shares of the stock in a transaction that occurred on Tuesday, April 11th. The shares were sold at an average price of $36.06, for a total transaction of $243,405.00. Following the completion of the sale, the chief executive officer now directly owns 4,730 shares in the company, valued at $170,563.80. The disclosure for this sale can be found here. Over the last three months, insiders sold 68,082 shares of company stock worth $2,696,566. Insiders own 4.90% of the company’s stock.
About Portola Pharmaceuticals
Portola Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients having limited or no approved treatment options. The Company’s two lead programs, Betrixaban and Andexanet alfa, address unmet medical needs in the area of thrombosis, or blood clots.
Receive News & Ratings for Portola Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Portola Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.